1. Introduction {#sec1}
===============

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the brain, optic nerves and spinal cord. Involvement of gray matter in MS has long been recognized in pathology studies ([@bb001]; [@bb002]; [@bb003]; [@bb004]; [@bb005]), yet MS has been considered to be predominantly a white matter disease due to more readily detected focal inflammatory demyelinating pathology in white matter by histology and by MRI. Evidence exists that damage occurs frequently in NAWM ([@bb006]; [@bb007]; [@bb008]) and cortical gray matter ([@bb009]; [@bb0010]; [@bb0011]). Damage occurring in each of these regions contributes to brain atrophy seen commonly in MS ([@bb0012]; [@bb0013]). Importantly, cortical lesions and cortical atrophy (which are presumed to be linked) are early findings in many RRMS patients, and correlate with disability, especially cognitive disability ([@bb0014]; [@bb0015]; [@bb0016]). Loss of cortical volume in MS does not occur in a uniform pattern, but is seen more often in specific regions such as the cingulate gyrus and insular regions ([@bb0015]).

Unfortunately, imaging of cortical MS lesions using the MRI technique has been challenging. Although conventional T2-weighted and FLAIR MRI sequences can detect many white matter lesions, these sequences do not readily detect damage in cortical gray matter or NAWM. Many MRI techniques, such as DIR (double inversion recovery) ([@bb0017]; [@bb0018]; [@bb0019]), diffusion ([@bb0020]; [@bb0021]; [@bb0022]), MT (magnetization transfer) ([@bb0023]; [@bb0024], [@bb0025], [@bb0025]; [@bb0026]; [@bb0027]; [@bb0028]) and transverse relaxation rate related measurement at ultra-high field ([@bb0029]; [@bb0030]), have been used to improve the detection of cortical MS damage. However, for various reasons, none of them have made it into clinical practice yet.

Gradient echo plural contrast imaging (GEPCI) is a technique based on a gradient recalled echo sequence with multiple gradient echoes ([@bb0031]; [@bb0032]; [@bb0033]). GEPCI allows simultaneous generation of naturally co-registered multi-contrast images (T1-weighted or spin density images, quantitative tissue-specific T2^\*^ or R2^\*^ maps and frequency maps) from a single MRI scan. By combining basic GEPCI images, additional images can be generated, such as SWI-like images, GEPCI-SWI images, T1f images, Fluid suppressed T2^\*^ (FST2^\*^) images, and SWI-T2^\*^ images ([@bb0031]). Previously, using the quantitative nature of GEPCI R2^\*^ measurements, we introduced quantitative GEPCI scores of tissue damage in WM lesions ([@bb0032]) and demonstrated in a small cohort that quantitative GEPCI scores of cerebral WM (not including GM) correctly categorized patients into RRMS vs. SPMS vs. PPMS in 70% of cases ([@bb0034]). GEPCI phase images also demonstrated a potential for early MS lesion detection ([@bb0035]).

In this study, we use two outcomes of GEPCI approach -- quantitative tissue specific R2^\*^ maps and GEPCI T1 weighted images -- to study 29 MS subjects and 21 healthy controls. We applied R2^\*^ analysis to evaluate global and regional tissue integrity in MS brains, with particular focus on the cortical gray matter. The results showed significant differences between the healthy and MS cohorts. R2^\*^ results correlated with clinical and neurocognitive test scores in the MS group. Based on quantitative R2^\*^ analysis, we introduced an exhibition method, "GEPCI-barcode," to illustrate the severity of tissue damage in different brain regions in individual subjects, and to allow easy evaluation of local tissue damage based on R2^\*^ measurements.

2. Materials and methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

Thirty MS patients with prior and clear designations as having relapsing remitting, secondary progressive or primary progressive clinical courses were invited to enroll in the study. MRI scans were collected from 10 RRMS, 10 PPMS and 10 SPMS patients. Data from one SPMS subject could not be included in final analyses because of pervasive "cloud-like" artifacts ([@bb0036]) caused by physiological fluctuations during the scan. The twenty one normal healthy control volunteers consisted of seven males and fourteen females, ranging in age from 21 to 74 years (age mean ± SD: 44.3 ± 14.9), were specifically chosen to represent the age range of the MS patients ([Table 1](#t0005){ref-type="table"}). All studies were approved by the Institutional Review Board of Washington University in St Louis. All subjects provided informed consent.

2.2. Clinical testing {#sec2.2}
---------------------

EDSS, a standardized neurological examination validated for use in MS, was performed by a certified examiner (AHC). Additionally, gait was assessed by 25FTW and bilateral upper extremity function was assessed by 9HPT. The PASAT, a test of auditory information processing speed and calculation ability, and SDMT, a test of visual processing speed, each validated in MS, were used to assess cognition. All testing was performed by experienced examiners on the same day as MRI, without knowledge of the imaging results.

2.3. Image acquisition {#sec2.3}
----------------------

All MRI scans were collected using a 3.0 Tesla (3 T) Trio MRI scanner (Siemens, Erlangen, Germany) equipped with a 12-channel phased-array head coil. High resolution GEPCI ([@bb0031]; [@bb0032]; [@bb0033]) datasets with a voxel size of 1 × 1 × 3 mm^3^ were acquired using a three dimensional (3D) multi-gradient-echo sequence with a flip angle of 30°, TR = 50 ms and total acquisition time of 6 min 30 s. For each acquisition, 11 echoes were collected with first echo time TE1 = 4 ms and echo spacing ΔTE = 4 ms. The multi-echo datasets were used for calculation of R2^\*^. Standard clinical MPRAGE ([@bb0037]) images with high resolution (voxel size: 0.94 × 0.94 × 1.5 mm^3^) were also collected for segmentation purposes.

2.4. Image processing {#sec2.4}
---------------------

Raw k-space data were read into MATLAB (The MathWorks, Inc.) for processing. After applying Fourier transform to the k-space, data from different channels were combined for each voxel in a single data set *S*(*TE*) using a strategy developed in house ([@bb0031]; [@bb0038]):$$\begin{array}{l}
{S(TE) = \frac{1}{M}{\sum\limits_{m = 1}^{M}\lambda_{m}}\overline{S}\left( {TE_{1}} \right)S_{m}\left( {TE_{n}} \right)} \\
{\lambda_{m} = {{\frac{1}{M}{\sum\limits_{l = 1}^{M}\sigma_{l}^{2}}}/\sigma_{m}^{2}}} \\
\end{array}$$where the sum is taken over all channels (m), $\overline{S}$ denotes complex conjugate of *S*, *λ~m~* is the weighting parameter and σ~*m*~ is the noise amplitude (r.m.s.). We omit index corresponding to voxel position for clarity. This algorithm allows for the optimal estimation of quantitative parameters, such as magnetic resonance signal decay rate constants and also removes the initial phase incoherence between channels. R2^\*^ constants were obtained by fitting the channel-combined data on a voxel-by-voxel basis using the following theoretical model:$$S(TE) = S_{0}^{2} \cdot e^{- R_{2}^{\ast} \cdot {({TE + TE_{1}})}} \cdot e^{i \cdot \omega}{}^{\cdot {({TE - TE_{1}})}} \cdot F\left( {TE} \right)$$where *ω* is a local signal frequency and *F*(*TE*) is the F-function describing the influence of macroscopic magnetic field inhomogeneity effects on MRI signal ([@bb0039]). Herein, we use a voxel spread function algorithm ([@bb0040]) for evaluation of F-function. With our choice of TR and flip angle, *S*~0~ represents T1-weighted images. Brain segmentation and volumetric information was obtained from MPRAGE images using FreeSurfer (Martinos Center for Biomedical Imaging, MGH/HST, US). Then, ROIs were registered on GEPCI-T1w images using FSL (Analysis Group, FMRIB, Oxford, UK). Last, regional R2^\*^ median values were generated and used for further analysis, as shown in [Fig. 1](#f0005){ref-type="fig"}. Note that to minimize the partial volume effect, CSF masks were also generated based on the GEPCI T1w images using FSL (step F in [Fig. 1](#f0005){ref-type="fig"}). Volumetric data were calculated from the segmentation results by multiplying the number of voxels inside each brain region by the size of voxels. Then, normalization factors were calculated using the "SIENAX" tool in "FSL" and applied to each region to get normalized volumes. Normalized brain volume (NBV) data were also obtained from the "SIENAX" results in "FSL".

2.5. ROI creation {#sec2.5}
-----------------

First (step A in [Fig. 1](#f0005){ref-type="fig"}), GEPCI-T1-weighted (S~0~) images and R2^\*^ maps were generated according to [Eq. (2)](#eqn2){ref-type="disp-formula"}. Both GEPCI-T1-weighted and GEPCI-R2^\*^ images were put into FSL ([@bb0041]; [@bb0042]; [@bb0043]) to remove the skull. Then, MPRAGE images were put into FreeSurfer (Laboratory for Computational Neuroimaging, Martinos Center for Biomedical Imaging) to generate brain segmentations and regional masks (steps B and C in [Fig. 1](#f0005){ref-type="fig"}), which include masks for global and regional cortical gray matter, NAWM and deep gray matter (caudate, putamen, globus pallidus and thalamus). At the same time, after removing skull using FSL, MPRAGE images were registered to GEPCI-T1-weighted images using FMRIB\'s Linear Image Registration Tool ([@bb0044]; [@bb0045]) in FSL (step D in [Fig. 1](#f0005){ref-type="fig"}) to get registration matrices. Then, the registration matrices were used to map the segmentation on GEPCI-R2^\*^ maps (step E in [Fig. 1](#f0005){ref-type="fig"}), which are naturally co-registered with GEPCI-T1-weighted images when using the GEPCI technique. To minimize the partial volume effect, CSF masks were also generated based on the GEPCI T1 weighted images using FSL (step F in [Fig. 1](#f0005){ref-type="fig"}). Note that in step B for MS subjects, we first used MPRAGE and FLAIR images to get WM lesion mask using the "lesion-TOADS" tool ([@bb0046]) in MIPAV ([@bb0047]). Then, we filled the lesion areas with averaged signal from normal tissue. These lesion-filled-MPRAGE images were used for segmentation for MS subjects. By doing this, we can minimize the topological defects caused by large lesions.

2.6. Statistical analysis {#sec2.6}
-------------------------

All statistical analyses were performed using MATLAB (The MathWorks, Inc.). For each ROI generated as described above, there was a distribution of R2^\*^ for which a median value was calculated. Median R2^\*^ values were used because distribution functions in each region were not symmetric. Regional R2^\*^ median values were calculated for each FreeSurfer region in each subject by applying regional and CSF masks to GEPCI R2^\*^ maps. Because age affects R2^\*^ ([@bb0048]) and volume ([@bb0049]), MS subject data were corrected for age using baseline data obtained from the healthy subject cohort. Linear regression analysis of median R2^\*^ values was used to define age-dependent baseline median R2^\*^ values for each region. Based upon this formula, for each ROI for each MS subject, the age-dependent baseline median R2^\*^ value for the healthy control subjects was subtracted from the MS subject\'s R2^\*^ median value to obtain the age-corrected parameter, ΔR2^\*^. The same procedure was used to create age-corrected tissue volumes, termed ΔV. In cortical GM regions, due to partial volume effect, variation in cortical thickness was also taken into account. In these regions, we adjusted R2^\*^ with respect to both age and cortical thickness using multiple linear regression to create ΔR2^\*^. For each brain ROI, ANOVA was used to compare ΔR2^\*^ and ΔV of the HC with MS subjects representing three clinical subtypes. Pearson\'s correlation was used to evaluate the correlation between ΔR2^\*^ or ΔV values and clinical scores. Correlation coefficients (r) and p-values (p) were calculated. False discovery rate was used to correct for multiple comparisons. In all cases, a p-value \<0.05 was considered as statistically significant.

2.7. GEPCI-barcode {#sec2.7}
------------------

To allow easier assimilation and comparison of the separate cortical regions, NAWM and deep gray matter regions being examined in each individual, we developed a visualization method we named "GEPCI barcode" to not only show easily distinguishable differences between healthy and MS cohorts and among different subtypes, but also to provide a potentially machine-readable representation of data relating to the regional abnormalities for each individual. For each brain ROI, the mean values (MEAN~HC~) and standard deviations (STD~HC~) of the ΔR2^\*^ values of the healthy group were calculated. Then, z-scores were calculated for all ROIs of each MS subject using:$$z = \frac{\Delta R2_{MS}^{\ast} - MEAN_{HC}}{STD_{HC}}$$where is the ΔR2^\*^ value calculated from distinct brain ROIs of each MS subject. All brain ROIs with z-scores between −1.96 and 1.96 were considered as normal and are shown as white squares on the barcode. Brain ROIs with z-scores less than −1.96 but greater than −2.58 were considered as regions with damage and are shown as unfilled red squares. Brain ROIs with z-scores less than −2.58 were considered as regions with severe damage, and were assigned completely red squares. Brain regions with z-score greater than 1.96 were considered as regions with high R2^\*^ values of unclear significance, and were designated unfilled blue (z-score greater than 1.96 but less than 2.58) or fully blue squares (z-score \> 2.58) on the barcode.

3. Results {#sec3}
==========

3.1. Cortical ROIs {#sec3.1}
------------------

ΔR2^\*^ values of the HC and MS cohorts in the global and regional cortical GM ROIs were compared. Data from right and left sides for individual regions were combined. The MS cohort showed lower ΔR2^\*^ values in the global cortical GM, compared with the HC cohort ([Fig. 2](#f0010){ref-type="fig"}A). When comparing different MS subtypes, the SPMS group showed the lowest ΔR2^\*^ values and had the greatest number of abnormal regions, with significantly (p \< 0.05) lower ΔR2^\*^ values in 25 of 31 cortical regions compared with the same regions in the HC ([Table A.1](#t0010){ref-type="table"}). MS subjects also showed significantly reduced ΔV values. Although many regions with reduced ΔV values also had reduced ΔR2^\*^ values, in a few regions ΔV was more sensitive whereas in others ΔR2^\*^ was more sensitive to abnormalities. Progressive MS subjects had more severe age-adjusted brain atrophy, compared to RRMS subjects. PPMS cohort had significantly decreased ΔV in 18 of 31 cortical regions, while SPMS cohort had significantly decreased ΔV in 24 of 31 cortical regions, compared to HC ([Fig. 2B](#f0010){ref-type="fig"} & [Table A.1](#t0010){ref-type="table"}).

3.2. Non-neocortical brain ROIs {#sec3.2}
-------------------------------

[Fig. 2C](#f0010){ref-type="fig"} reveals that the MS cohorts had lower ΔR2^\*^ values in NAWM compared with the HCs. Significant NAWM volume loss was also found in RRMS and SPMS subjects ([Fig. 2D](#f0010){ref-type="fig"}). In the globus pallidus ([Table A.1](#t0010){ref-type="table"}), the ΔR2^\*^ values in the RRMS cohort were higher than the ΔR2^\*^ values in HC. SPMS and PPMS cohorts had overall higher ΔR2^\*^ in globus pallidus than the HC cohort but lower ΔR2^\*^ than the RRMS cohort. No significant differences were found for ΔR2^\*^ values in the caudate, putamen and thalamus regions between HC and any of the MS cohorts ([Table A.1](#t0010){ref-type="table"}). ΔV values were significantly reduced in the putamen, globus pallidus, caudate and thalamus in MS subjects ([Table A.1](#t0010){ref-type="table"}). Significant correlation was found between ΔR2^\*^ changes in the cortex and in the thalamus (r = 0.43, p = 0.002). Only moderately significant correlation was found between ΔR2^\*^ changes in the cortex and in the caudate (r = 0.31, p = 0.03) regions. No significant correlations were found between ΔR2^\*^ changes in the cortex and in putamen or globus pallidus regions.

3.3. Correlations between regional ΔR2^\*^ and ΔV values and clinical tests {#sec3.3}
---------------------------------------------------------------------------

SDMT and PASAT assess visual working memory speed and auditory working memory speed, respectively. ΔR2^\*^ values calculated from the global cortical GM region correlated significantly with SDMT (r = 0.60, p \< 0.001) and 3 s PASAT (r = 0.53, p = 0.003) cognitive tests ([Fig. 3](#f0015){ref-type="fig"}A & B).

ΔR2^\*^ values in the hippocampus and many individual cortical regions also showed significant correlations with SDMT and PASAT scores as well ([Table A.2](#t0015){ref-type="table"}). ΔR2^\*^ values of several cortical regions correlated significantly (r \> 0.4, p \< 0.05) with cognitive tests (ROIs in "bold" in [Table A.2](#t0015){ref-type="table"}). Correlations between cognitive tests and age-adjusted *whole* brain volumes (ΔNBV) were also found ([Fig. 3C & D](#f0015){ref-type="fig"}), but no significant correlations were found between normalized regional age-adjusted volumes of cortical GM and cognitive test scores ([Table A.2](#t0015){ref-type="table"}). The multiple linear regression method was also used to test correlations between cognitive scores (SDMT and PASAT) and MRI measurements (ΔR2^\*^ of cortical gray matter; ΔNCGMV: age-adjusted normalized cortical GM volume; WMLL: white matter lesion load). For SDMT scores, the p-values for ΔR2^\*^, ΔNCGMV and WMLL were 0.003, 0.65 and 0.05, respectively. For PASAT scores, the p-values for ΔR2^\*^, ΔNCGMV and WMLL were 0.005, 0.35 and 0.75, respectively. The EDSS, 25FTW and 9HPT, neurological tests that primarily assess strength, coordination, gait, and upper extremity function, showed no significant correlations with global or regional cortical GM ΔR2^\*^ values. The 25FTW correlated inversely with ΔNBV (r = −0.37, p = 0.047) and normalized age-adjusted GM volume (r = −0.41, p = 0.026). No other correlations were found for ΔV values.

3.4. GEPCI-barcode {#sec3.4}
------------------

Averaged cortical z-score maps (from which GEPCI barcodes are derived) for four groups are shown in [Fig. 4](#f0020){ref-type="fig"}. From these z-score maps, it is apparent that most SPMS subjects have much lower GEPCI z-scores affecting almost the entire cortex.

[Fig. 5](#f0025){ref-type="fig"} shows a summary barcode for all the subjects. As expected, most brain regions in the HC subjects were normal (white, [Fig. 5](#f0025){ref-type="fig"}). Four HC subjects showed abnormally low ΔR2^\*^ values in a few regions (1.2% of all regions, 1.2% of cortical GM regions in all HCs). This may be explained because we selected \[−1.96, 1.96\] as a range to define normal ΔR2^\*^, which contained about 95% of the total regions in HC subjects with the other 5% located outside the normal range. It is also possible that those HC subjects had real abnormalities of unknown etiology. In contrast, many brain regions of the MS subjects were abnormal (red unfilled or red filled squares for low ΔR2^\*^; or blue unfilled or filled for high ΔR2^\*^, [Fig. 5](#f0025){ref-type="fig"}). For cortical gray matter, the percentage of regions with abnormal tissue integrity based on GEPCI ΔR2^\*^ values for RRMS, PPMS and SPMS subjects was 0%, 30% and 67%, respectively.

Cortical damage, inferred from the reduced ΔR2^\*^ values, was more widespread in the SPMS cohort than the other two MS clinical subtype cohorts as illustrated with "GEPCI-barcode", with 8 of 9 SPMS subjects displaying several cortical regions of reduced ΔR2^\*^. Interestingly, 3 of those 7 did not display reduced ΔR2^\*^ in NAWM, supporting the finding that damage to cortical gray matter and white matter is not highly linked ([@bb0050]).

Using the GEPCI-barcode, 10% of RRMS, 30% of PPMS and 33% of SPMS subjects showed abnormally low ΔR2^\*^ (red & black) in NAWM ([Fig. 5](#f0025){ref-type="fig"}). Regarding deep gray matter regions, in the globus pallidus, 50% of RRMS showed abnormally high ΔR2^\*^, with fewer of the PPMS (10%) and SPMS (22%) groups with increased ΔR2^\*^ in deep gray matter.

4. Discussion {#sec4}
=============

In this study, we used tissue specific quantitative R2^\*^ values as biomarkers for tissue alterations in MS brain with particular attention to the global and regional cerebral cortex where tissue damage is poorly appreciated using standard MRI techniques. Our results conclusively support the known neuropathology of MS as a global brain disease affecting both gray and white matter. The GEPCI technique, which requires less than 7 min to acquire on standard clinical MRI scanners, detected abnormalities within regions without visible lesions, such as cortical gray matter, NAWM and deep gray matter. The measured R2^\*^ values were referenced to age-dependent HC values. The majority of white matter abnormalities were reductions in R2^\*^, which were indicative of damage based on our and others\' earlier work ([@bb0051]; [@bb0052]; [@bb0032]). Further, we developed a presentation technique called "GEPCI-barcode" to display these quantitative results intuitively.

MS is a demyelinating disease of the CNS, the cause of which is yet unknown. Because it is demyelinating, it has long been considered as a white matter disease, despite the fact that myelin is also present in gray matter and initial pathology studies in the early and mid-1900s had demonstrated that both white matter and gray matter are involved ([@bb0053]). Reasons for the lack of attention to gray matter pathology include that focal inflammatory demyelination in gray matter provides less contrast using standard histological stains (e.g. Luxol fast blue and hematoxylin) because of the lower baseline myelin content and less prominent cellular inflammation in gray matter lesions compared with white matter MS lesions. Moreover, the pathologic changes in white matter create more conspicuous manifestations on MRI, including not only the typical hyperintensities on T2w images, but in some cases hypointensities ("black holes") on T1w images. The latter are practically never seen in gray matter. In addition to being difficult to detect on T1w and T2w images, cortical gray matter lesions have only rarely been described to enhance post-gadolinium ([@bb0054]).

Yet, cortical gray matter lesions are exceedingly important in MS, and can occur very early in disease ([@bb0055]). Conservatively, cognitive problems affect close to half of MS patients ([@bb0056]). Imaging measures reflecting cortical gray matter MS pathology, such as cortical thickness and assessment of cortical lesion numbers by DIR, correlate with cognition in RRMS ([@bb0014]; [@bb0057]), and SPMS ([@bb0058]; [@bb0059]). In contrast, measures of white matter and deep gray matter pathology (lesion volumes, black hole volumes, white matter volumes) correlate less well if at all with cognition ([@bb0060]). Notably, cortical lesions are conspicuously sparse in patients with "benign" MS ([@bb0061]).

Detection of cortical MS lesions using imaging in MS patients has been challenging. DIR techniques can increase cortical lesion detection ([@bb0017]; [@bb0018]; [@bb0019]), but DIR is insensitive, missing more than half of cortical MS lesions detected by histopathology ([@bb0062]; [@bb0063]). Ultra-high field MRI detects more cortical lesions, but it is not available in most medical centers ([@bb0064]). Non-standard imaging techniques have been applied to the detection of cortical MS lesions, including magnetization transfer and diffusion tensor imaging. Cortical abnormalities detected by magnetization transfer have been reported ([@bb0023]; [@bb0024], [@bb0025]; [@bb0026]; [@bb0027]). The findings from these studies suggested that high field and high resolution were necessary for cortical lesion detection using magnetization transfer ratio. Most of these studies were done on post-mortem brains and validated in vivo results are needed for applying this technique to clinical use. Diffusion tensor imaging is quantitative, and detects cortical gray matter tissue pathology (as reduced fractional anisotropy). Diffusion measures have been reported to correlate with disability, including cognitive dysfunction ([@bb0020]; [@bb0022]). Application of diffusion measures in cortical gray matter, and the associations with cognitive function are still being elucidated ([@bb0021]).

GEPCI ([@bb0031]; [@bb0032]; [@bb0036]; [@bb0033]) is a relatively new technique, which provides high-resolution, co-registered, multi-contrast images within a single scan that can be performed in less than 7 min on standard MRI scanners ([@bb0034]). In this study we explored two GEPCI images --- T1w and R2^\*^ maps. T1w images were used for image registration while R2^\*^ maps were used to quantify tissue "health status". Because GEPCI can provide quantitative R2^\*^ (and T2^\*^) maps, it can be used to quantitatively detect subtle tissue damage in different brain regions. Previously we used GEPCI to quantitate tissue damage in white matter lesions ([@bb0032]). In the present study, we report that the quantitative parameter R2^\*^ can also evaluate tissue damage in cortical gray matter and in NAWM. Our MS subject cohort showed overall substantially lower R2^\*^ values in both cortical gray matter and NAWM ([Fig. 2](#f0010){ref-type="fig"}). GEPCI data appear to provide information that is complementary to the published atrophy data ([@bb0058]; [@bb0012]; [@bb0014]; [@bb0057]; [@bb0016]). Indeed our results demonstrated that not only volume but also health of the tissue as defined by R2^\*^ declined in brain regions that are also prone to suffer volume loss in MS.

Based on quantitative R2^\*^ analysis, we introduced in this paper a technique called "GEPCI-barcode" to illustrate regional GEPCI results, with the idea that this method might be applied to individually label each patient\'s brain tissue "health status" and follow changes in the patients\' brain tissue health longitudinally. Most MS subjects in our studies had some cortical regions of R2^\*^ abnormality. Not unexpectedly, PPMS and SPMS subjects showed more widespread cortical abnormalities than RRMS subjects; this was readily apparent by viewing data using GEPCI-barcode. Abnormalities of R2^\*^ were predominantly located in the frontal, temporal, central and cingulate regions, including the caudal middle frontal, lateral orbitofrontal, paracentral, postcentral, precentral, superior temporal and isthmus of the cingulate gyrus cortical regions. Many previous studies also found that it was mainly these same regions that showed cortical atrophy in MS patients ([@bb0065]; [@bb0066]; [@bb0067]).

Previous ex vivo studies have shown that both white matter and cortical MS lesions have shorter R2^\*^ (longer T2^\*^) due to myelin and iron loss ([@bb0068]; [@bb0069]). In accord, our MS cohort had substantially lower R2^\*^ in cortical regions compared to the healthy cohort. Moreover, GEPCI-barcode revealed more abnormal cortical regions in the SPMS than PPMS cohort in our study. This result is consistent with previous pathology studies that reported cortical demyelination in SPMS subjects to be more widespread and severe than in PPMS subjects ([@bb0070]; [@bb0071]). The same study also suggested that cortical damage was distributed throughout the forebrain, especially in the deep sulci of the temporal, cingulate, insula and frontal cortex. Our results are highly consistent with this. Recently, Mainero et al. using high resolution T2^\*^ mapping obtained with high field (7 T) MRI revealed that cortical pathology has a depth dependence ([@bb0030]). Their results showed that in early MS, regions with higher T2^\*^ (lower R2^\*^) were mainly located in the outer layers in the rostral anterior cingulate, parietal, precentral and postcentral regions. As disease progressed, the regions with higher T2^\*^ spread to all cortical depths and regions. Our averaged z-score map ([Fig. 4](#f0020){ref-type="fig"}) showed a similar pattern with regard to affected regions. For RRMS, the regions with lower z-scores are mainly located in the lateral occipital, parietal, cuneus, pericalcarine, precuneus, precentral and postcentral regions. For SPMS, almost all cortical regions showed low z-scores compared to other groups.

From GEPCI-barcode, we also found that one RRMS, two PPMS and four SPMS subjects showed reduced R2^\*^ in the hippocampus, a region that is crucial for episodic memory. ΔR2^\*^ measurements in this region correlated well with SDMT and PASAT scores ([Fig. 3](#f0015){ref-type="fig"}). In our study, 6 of 7 subjects with reduced R2^\*^ in the hippocampus on GEPCI-barcode scored poorly on SDMT and PASAT testing. Again, our results are consistent with studies in which hippocampal atrophy had been found mainly in patients with severe cognitive impairment ([@bb0072]; [@bb0073]). These data strongly support our interpretation of reduced R2^\*^ to indicate hippocampal damage.

Quantitative R2^\*^ analysis of global cortical gray matter showed convincing correlations with clinical cognitive tests (SDMT and PASAT). Because both SDMT and PASAT assess cognitive function in which cortical gray matter plays a critical role, this suggests that R2^\*^ can serve as a sensitive biomarker to characterize tissue functional viability. Notably, ΔR2^\*^ values in some specific cortical regions showed strong correlations with clinical cognitive tests. The correlation between the PASAT, a measure of auditory information processing speed, and ΔR2^\*^ values of the superior-temporal region, which is critical for auditory processing (r = 0.62, p = 0.01), supports the relevance of the GEPCI data.

We found no correlations between cortical ΔR2^\*^ values and EDSS, 25FTW and 9HPT. These results were initially surprising, given prior papers finding correlations between GM volumes and impairment measures such as EDSS and 25FTW. However, early studies with strong correlations to EDSS often reported correlations for whole GM, including subcortical GM structures ([@bb0074]; [@bb0075]). Others found only weak correlations between global or regional cortical thickness and physical impairment measures ([@bb0076]; [@bb0077]) or none ([@bb0078]; [@bb0079]). Many studies showing larger correlations have not accounted for age ([@bb0080]). Our results are in keeping with the findings of Shiee et al., who found no correlation between cortical volumes and EDSS, 25FTW and 9HPT in MS patients of varying subtypes ([@bb0081]). As the EDSS, 25FTW and 9HPT all measure primarily motor function and coordination, where the cerebellum and spinal cord play more important roles than the cerebral cortex, our results are not too surprising.

Importantly, our results show that regions of cortical atrophy not only suffer tissue loss but also experience tissue structural changes. Indeed, cortical damage detected by R2^\*^ measurements occurred mainly in the same regions that showed cortical atrophy in previous reports in MS patients ([@bb0065]; [@bb0066]). Our data confirmed volume loss in almost all of the same individual brain regions. Volume loss has been reported to correlate with cognitive impairment in RRMS ([@bb0014]; [@bb0057]). Longitudinal studies have also shown that volume loss correlates with disability ([@bb0082]; [@bb0083]). In our cross-sectional study, we found that regional cortical GM volumetric data showed significant differences between healthy and MS cohorts, but no significant correlations of regional volumes were found with cognitive tests ([Table A.2](#t0015){ref-type="table"}). In contrast, R2^\*^ data showed significant correlations with cognitive tests, suggesting that R2^\*^ can provide information on tissue damage in the cortex that is different and complementary to volume information.

In the deep nuclei area, especially in the globus pallidus, RRMS subjects tended to have higher R2^\*^ values compared with age-matched HC subjects ([Table A.1](#t0010){ref-type="table"}). This is perhaps explained by excess iron accumulation in these regions, but it was curious that our progressive SPMS and PPMS cohorts demonstrated less alteration in R2^\*^ in the globus pallidus than the RRMS cohort. The reason for this is unclear, but may relate to a combination of both reduction of R2^\*^ due to tissue integrity loss and increase in R2^\*^ due to iron which serve to off-set one another in the older progressive patients to a larger degree than in the RRMS cohort.

Since cortical gray matter is relatively thin, it is important to apply methods that would reduce the influence of partial volume effects, especially signal contamination by CSF. To address this issue in our studies we used imaging with high in-plane resolution (1 mm × 1 mm). We also applied a CSF mask to remove CSF signals that might contaminate our results and we used statistical measurements instead of a voxel-based analysis. For each region, which usually contains thousands of voxels, we generated a single parameter --- median value of R2^\*^ distribution because the median value is less sensitive to outliers (that might be related to partial volume effect). In our analysis of R2^\*^ in the cortical GM regions, we did multiple linear regression of R2^\*^ measurements with both age and cortical thickness to account for age and atrophy effects.

5. Conclusion {#sec5}
=============

Our findings showed that, overall, using tissue specific R2^\*^ measurements we could detect and measure cortical abnormalities in MS patients using a standard MRI scanner, and with a very short clinically acceptable scan time. The correlations between cognitive functioning and specific gray matter R2^\*^ values provided evidence that R2^\*^ is intrinsically related to tissue-specific pathology, and R2^\*^ measurements can be used to evaluate tissue integrity. These are critical findings, as the field has great need of a quantitative method to detect cortical damage that will improve upon and complement measures of volume, which are currently the most useful measure of cortical damage ([@bb0082]). Our results suggest that clinical trials, especially early phase trials using imaging as a primary endpoint, might benefit by including GEPCI measures. In future studies, we will examine larger numbers of subjects and employ methods to correct physiologically-induced artifacts ([@bb0036]). Our goal is to develop an easy and universally applicable quantitative method to detect CNS damage to aid in patient management and use in multi-center clinical trials.
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Table A.1p-Values for group differences in 37 gray matter regions identified by FreeSurfer. Significant p-values (p \< 0.05) are in bold. False discovery rate \[FDR\] correction for multiple comparisons was applied to all regions.ROIΔR2^\*^Δ volumeHC vs. RRHC vs. PPHC vs. SPRR vs. PPRR vs. SPPP vs. SPHC vs. RRHC vs. PPHC vs. SPRR vs. PPRR vs. SPPP vs. SPCaudal anterior cingulate0.7620.9490.4810.9590.9640.5980.7410.3850.0830.8070.3020.804Caudal middle frontal0.3410.101**\<0.001**0.819**0.039**0.2630.1950.1540.1840.9990.9160.960Cuneus**0.041**0.577**\<0.001**0.8190.2870.255**0.0490.0210.003**0.9990.4580.804Fusiform0.1360.101**\<0.001**0.9860.1000.244**0.0090.001\<0.001**0.8070.1130.819Inferior parietal0.2780.071**\<0.001**0.819**0.039**0.244**0.0490.008\<0.001**0.8070.1200.804Inferior temporal0.2740.554**0.003**0.8190.1350.2440.084**0.050**0.3280.9990.6840.819Isthmus of cingulate0.4360.357**0.004**0.9860.3000.4110.6430.5300.5280.8070.8960.804Lateral\
Occipital**0.041**0.071**\<0.001**0.9860.1010.2440.058**0.007\<0.001**0.8070.3020.804Lateral orbitofrontal0.6920.949**0.029**0.819**0.048**0.2440.059**0.0050.005**0.8070.5730.921Lingual0.0770.306**\<0.001**0.9590.0670.244**0.0210.0270.001**0.9990.3040.804Medial orbitofrontal0.4320.8890.6090.8190.2840.9330.4990.088**0.018**0.8070.3910.837Middle temporal0.8040.086**0.004**0.8190.1440.569**0.0150.0220.001**0.9990.6380.804Parahippocampal0.7380.215**\<0.001**0.819**0.039**0.2440.134**0.0270.012**0.8070.4160.837Paracentral0.3020.128**\<0.001**0.9590.1090.2440.066**\<0.0010.0010.012**0.3020.804Pars opercularis0.8080.137**\<0.001**0.819**0.018**0.244**0.0490.0020.009**0.8070.7020.837Pars orbitalis0.7380.357**0.006**0.819**0.039**0.2990.088**0.0050.017**0.8070.6380.804Pars triangularis0.7380.137**\<0.001**0.819**0.004**0.244**0.0110.005\<0.001**0.9990.3020.804Pericalcarine0.2600.889**0.001**0.8190.1450.2440.058**0.0210.001**0.9820.3020.804Postcentral0.4320.159**\<0.001**0.819**0.018**0.244**0.0210.0020.002**0.8070.5730.837Posterior cingulate0.7230.5310.3520.9850.8600.958**0.0140.022\<0.001**0.9990.1970.804Precentral0.3020.071**\<0.001**0.819**0.039**0.314**0.0390.0010.003**0.8000.5210.819Precuneus0.0770.071**\<0.001**0.9590.1260.275**0.0390.0060.007**0.8070.5210.960Rostral anterior cingulate0.7620.8890.6640.9860.4520.5980.3130.343**0.009**0.9990.3480.804Rostral middle frontal0.8910.137**0.003**0.819**0.039**0.2990.058**0.0400.014**0.9990.6380.861Superior frontal0.7380.137**0.001**0.819**0.039**0.2440.160**0.0030.009**0.8000.4420.804Superior parietal0.1360.202**\<0.001**0.9860.1010.244**0.0160.0010.001**0.8000.3020.960Superior temporal0.7620.086**\<0.001**0.819**0.027**0.275**0.0060.003\<0.001**0.9990.6380.861Supramarginal0.3390.137**\<0.001**0.819**0.039**0.2440.123**0.0010.001**0.4770.3210.804Frontal pole0.8910.6660.2320.8190.2840.5830.1620.2450.9080.9990.4160.804Transverse temporal0.7620.720**0.006**0.9860.2070.2440.5980.1540.0740.9990.6380.960Insula0.7620.9490.0810.9590.1780.357**0.050**0.347**0.030**0.8070.9710.804Thalamus0.3290.9490.3070.8190.6910.583**0.0390.0060.003**0.9990.8550.960Caudate0.7620.2820.3800.8280.3250.244**0.006\<0.0010.001**0.8630.8650.804Putamen0.7620.9490.4090.9590.7330.569**\<0.0010.001\<0.001**0.9990.5730.819Globus pallidus**0.041**0.1280.1520.8190.2800.871**0.0080.006\<0.001**0.9990.3970.804Hippocampus0.7620.889**0.008**0.9860.0650.2440.1490.1660.0200.9990.5210.804Amygdala0.1360.6250.4730.8190.3720.9880.1100.0880.0020.9990.3700.804

Table A.2Correlations between cognitive test scores and ΔR2^\*^ in 37 gray matter brain regions. Significant correlations (r \> 0.4, p \< 0.05) are in bold. False discovery rate \[FDR\] correction for multiple comparisons was applied to all regions.ROIΔR2^\*^Δ volumeSDMTPASAT (3 s)SDMTPASAT (3 s)rprprprpCaudal anterior cingulate0.2330.2750.3520.0840.3170.3000.2780.497Caudal middle frontal**0.5570.0140.4800.034**0.2590.3700.1760.800Cuneus**0.4600.028**0.4080.0540.2700.3700.0410.878Fusiform**0.5510.0140.5010.026**0.3930.2200.3600.347Inferior parietal**0.5140.0180.5170.023**0.4240.2070.4730.307Inferior temporal0.3500.1000.1920.3560.2460.3700.1980.768Isthmus of cingulate0.2360.2750.3640.0740.3780.2330.2960.452Lateral occipital0.3180.1330.3400.0940.5480.0800.4150.307Lateral orbitofrontal**0.4170.045**0.3830.0620.0230.9310.0600.878Lingual**0.5330.016**0.4120.0540.1880.432−0.0410.878Medial orbitofrontal0.3430.1060.2630.2000.1100.6580.0620.878Middle temporal0.2990.1580.3880.0610.1980.4270.3310.430Parahippocampal**0.4840.025**0.4100.0540.3500.2660.0650.878Paracentral0.2000.3560.2640.2000.3320.2990.1470.808Pars opercularis**0.4740.025**0.4050.0540.2030.4240.1580.808Pars orbitalis**0.4240.043**0.3950.057−0.3090.300−0.2360.634Pars triangularis**0.4740.0250.5250.023**0.3100.3000.1700.800Pericalcarine**0.4730.025**0.4210.0540.1810.440−0.0440.878Postcentral**0.4530.0290.4420.047**0.2280.3870.0860.878Posterior cingulate0.0470.8540.1480.4680.1930.4280.0780.878Precentral**0.5570.014**0.3960.0570.2920.3380.2030.768Precuneus**0.4680.0260.4570.040**0.1150.6570.0070.970Rostral anterior cingulate0.1660.4520.1930.3560.2590.3700.0990.878Rostral middle frontal**0.5250.0160.4580.040**0.0690.783−0.0460.878Superior frontal**0.4230.043**0.4060.0540.1550.5180.0290.907Superior parietal0.4030.0530.2950.1530.2220.3900.1350.821Superior temporal**0.5700.0140.6150.014**0.2380.3700.1700.800Supramarginal**0.5960.0140.5390.023**0.2380.3700.2410.634Frontal pole0.3760.075**0.5320.023**0.0500.843−0.0810.878Transverse temporal**0.4870.0250.5150.023**0.2110.4140.1530.808Insula0.3220.131**0.4560.040**0.0870.7300.0890.878Thalamus0.0140.9430.0540.7820.4440.2010.3020.452Caudate0.1480.4960.0920.6510.0100.960−0.0910.878Putamen−0.0640.805−0.1700.4120.4050.2200.3000.452Globus pallidus−0.0320.892−0.3790.0630.3680.2360.3820.312Hippocampus**0.5320.0160.5840.016**0.4490.2010.4230.307Amygdala0.2380.2750.4050.0540.2790.3610.1310.821
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![Flowchart of ROI creation. A. Calculation of T1-weighted images and R2^\*^ maps from raw data, brain was extracted using BET tool in FSL; B. Freesurfer used for brain segmentation; C. generation of regional masks based on the segmentation; D. registration of MPRAGE image onto GEPCI-T1-weighted image; E. regional masks mapped onto GEPCI images; F. GEPCI-T1w images used to generate CSF mask; G & H. calculation of median values of the R2^\*^ distribution in each ROI.](gr1){#f0005}

![ΔR2^\*^ and normalized volumes (ΔV) of global cortical GM and NAWM for HC and MS cohorts. A. Group comparisons for ΔR2^\*^ values in global brain cortical GM; B. group comparisons for ΔV values in global brain cortical GM; C. group comparisons for ΔR2^\*^ values in NAWM; D. group comparisons for ΔV values in NAWM.](gr2){#f0010}

![Cognitive test correlations with ΔR2^\*^ and with normalized whole brain volumes (ΔNBV). A. Correlation of ΔR2^\*^ of global cortical GM with SDMT scores; B. correlation of ΔR2^\*^ of global cortical GM with 3 s PASAT; C. correlation between ΔNBV and SDMT; D. correlation between ΔNBV and 3 s PASAT. Correlation coefficient (r) and p-values (p) are listed in each figure. Each point represents an individual subject. ΔNBV is the normalized whole brain volume after age correction. No significant correlations were found between regional age-adjusted cortical GM volumes and cognitive test scores ([Table A.2](#t0015){ref-type="table"}).](gr3){#f0015}

![Cortical z-score brain maps of ΔR2^\*^ in healthy, RRMS, PPMS and SPMS groups. For each cortical regions in each group, averaged z-scores were calculated across all subjects.](gr4){#f0020}

![GEPCI-barcodes for all brain regions studied in all subjects. ΔR2^\*^ values were calculated for various regions (x-axis) of each HC and MS subject (y-axis). z-Score values were calculated using mean value and standard deviation calculated from age-dependent ΔR2^\*^ values for each ROI in the whole HC cohort. White squares represent z-score values within the range −1.96 to 1.96 of the HC subjects, considered normal. Red and blue colors represent low and high ΔR2^\*^ values, respectively. Red empty squares represent z-score values less than −1.96 but greater than −2.58. Red filled squares represent z-score values less than −2.58. Blue empty squares represent z-score values greater than 1.96 but less than 2.58. Blue filled squares represent z-score values greater than 2.58.](gr5){#f0025}

###### 

Summary of subject demographic and clinical information.

  ----------------------------------------------------------------------------------------------------------------------------
                                MS               Normative data                                              
  ----------------------------- ---------------- ---------------- ---------------- ------------------------- -----------------
  Number                        10               10               9                                          

  Mean age ± SD\                49.4 ± 10.4\     55.2 ± 10.2\     59.2 ± 9.3\                                
  (range)                       (32--60)         (37--74)         (45--75)                                   

  Female/male                   9/1              6/4              7/2                                        

  SDMT mean ± SD (range)        54.6 ± 10.9\     42.5 ± 14.5\     44 ± 15.2\       62.1 ± 10.7 ([@bb0084])   
                                (32--68)         (10--61)         (18--63)                                   

  3 s PASAT mean ± SD (range)   49.0 ± 11.6\     40.4 ± 11\       37.9 ± 16\       49.7 ± 9.8 ([@bb0084])    
                                (21--59)         (21--56)         (15--58)                                   

  EDSS mean ± SD\               3.05 ± 1.7\      5.1 ± 1.3\       5.5 ± 1.1\       n/a                       
  (range)                       (1--6.5)         (3.5--6.5)       (4--6.5)                                   

  25FTW mean ± SD\              5.9 ± 2.5\       10.2 ± 9\        13.4 ± 11\       ≤5 ([@bb0085])            
  (range)                       (3.86--12.5)     (4.17--34.315)   (5.5--41.08)                               

  9HPT mean ± SD (range)        Dominant         23.4 ± 4.8\      30.1 ± 9.8\      27.5 ± 5.3\               ≤22 ([@bb0086])
                                                 (16.62--30.19)   (22.7--56.2)     (19.9--34.69)             

  Non-dominant                  28.2 ± 12.8\     31.3 ± 5.8\      38.4 ± 19.1\                               
                                (17.55--61.95)   (24.05--41.45)   (21.7--75.85)                              

  WMLL (ml) mean ± SD\          12.1 ± 13.0\     13.1 ± 9.6\      13.9 ± 10.0\                               
  (range)                       (1.3--40.1)      (2.3--29.2)      (6.4--36.7)                                

  NCGMV (ml) mean ± SD\         757.2 ± 47.5\    730.9 ± 55.8\    678.3 ± 61.1\                              
  (range)                       (703.2--835.0)   (648.9--844.4)   (551.2--759.1)                             
  ----------------------------------------------------------------------------------------------------------------------------

SDMT = symbol digit modalities test; PASAT = paced auditory serial addition test; EDSS = expanded disability status scale; 25FTW = 25-foot timed walk; 9HPT = nine-hole peg test; WMLL = white matter lesion load; NCGMV = normalized cortical gray matter volume.
